Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded by BidaskClub

BidaskClub downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a research note published on Wednesday morning, BidAskClub reports.

Several other research firms have also recently weighed in on ENTA. Zacks Investment Research cut Enanta Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Wednesday, July 17th. Wolfe Research began coverage on Enanta Pharmaceuticals in a research report on Friday, May 24th. They issued an outperform rating and a $117.00 price objective on the stock. Finally, Berenberg Bank raised Enanta Pharmaceuticals from a hold rating to a buy rating and boosted their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $109.00.

ENTA stock traded down $2.67 during midday trading on Wednesday, hitting $71.77. The company’s stock had a trading volume of 268,088 shares, compared to its average volume of 160,061. The company’s 50-day moving average is $83.66. Enanta Pharmaceuticals has a 1 year low of $64.08 and a 1 year high of $106.80. The stock has a market cap of $1.48 billion, a PE ratio of 20.17 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The business had revenue of $39.60 million for the quarter, compared to analysts’ expectations of $40.92 million. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The business’s revenue was down 10.0% on a year-over-year basis. On average, equities analysts forecast that Enanta Pharmaceuticals will post 2.06 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Pearl River Capital LLC lifted its position in shares of Enanta Pharmaceuticals by 174.5% during the 1st quarter. Pearl River Capital LLC now owns 280 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 178 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $49,000. South Dakota Investment Council purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $76,000. Valeo Financial Advisors LLC lifted its position in shares of Enanta Pharmaceuticals by 196.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 829 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 549 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at $258,000. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Article: Lock-Up Period Expiration

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.